Impact Therapeutics and Eikon Therapeutics Collaborate Globally to Develop and Commercialize PARP1 Selective Inhibitors
Friday, June 02, 2023
IMPACT Therapeutics and Eikon Therapeutics have recently announced a global license and collaboration agreement for the development of PARP1 selective inhibitors, including IMP1734. IMPACT Therapeutics is a biopharmaceutical company focused on discovering and developing targeted anti-cancer therapeutics based on synthetic lethality. Meanwhile, Eikon Therapeutics is a biotechnology company that integrates engineering and science to advance breakthrough therapies.
Under the collaboration agreement, Eikon has obtained an exclusive license from IMPACT to co-develop, register, manufacture, and commercialize IMP1734 and other PARP1 selective inhibitors globally, with the exception of Greater China (mainland China, Hong Kong, Macau, and Taiwan). The main objective of this partnership is to expedite the development of the PARP1 selective inhibitor program by combining the scientific, clinical, regulatory expertise, and financial resources of both companies.
IMPACT Therapeutics' CEO, Sui Xiong Cai, Ph.D., expressed enthusiasm about the partnership, emphasizing the successful track record of Eikon's leadership team in developing oncology medicines. The collaboration is expected to leverage the strengths of both companies to bring innovative cancer treatments, including PARP1 selective inhibitors, to patients in China and worldwide.
Roger M. Perlmutter, M.D., Ph.D., CEO, and Board Chair of Eikon Therapeutics, praised IMPACT's advanced discovery engine and its pipeline of molecules. He specifically mentioned senaparib, a dual PARP1/2 inhibitor developed by IMPACT, which has demonstrated improved outcomes in patients with advanced ovarian cancer. Eikon is confident in its ability to collaborate with IMPACT's scientists to develop IMP1734 and other selective PARP1 inhibitors, exploiting DNA damage response aberrations found in tumors to selectively target and eliminate cancer cells. By leveraging their expertise, resources, and proprietary technology platforms, Eikon and IMPACT aim to provide these important PARP1 inhibitor therapies to patients seeking new and more effective treatment options.
